XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 140,714,000 $ 113,688,000
Short-term investments 0 121,898,000
Accounts receivable, net ($4,178 and $6,079 from related parties) 6,412,000 12,553,000
Inventories 25,397,000 41,565,000
Prepaid expenses and other current assets 36,936,000 41,855,000
Total current assets 209,459,000 331,559,000
Restricted time deposits 1,658,000 1,658,000
Property and equipment, net 10,917,000 13,126,000
Equity method investment in unconsolidated variable interest entity 6,912,000 5,290,000
Operating lease right-of-use assets 61,212,000 68,093,000
Other assets 3,045,000 3,803,000
Total assets 293,203,000 423,529,000
Current liabilities:    
Accounts payable ($1,586 and $0 to a related party) 9,938,000 17,960,000
Accrued and other current liabilities ($10,993 and $39,814 to a related party) 113,574,000 172,891,000
Deferred revenue ($6,111 and $7,220 to related parties) 9,546,000 12,740,000
Operating lease liabilities, current 15,531,000 14,077,000
Total current liabilities 148,589,000 217,668,000
Product development obligations 17,397,000 17,763,000
Deferred revenue, net of current ($3,292 and $9,705 to a related party) 131,192,000 157,555,000
Operating lease liabilities, non-current 58,376,000 66,537,000
Senior secured term loan facilities, non-current 72,478,000 71,934,000
Liability related to sale of future revenues, non-current 54,532,000 51,413,000
Other long-term liabilities ($605 and $656 to a related party) 1,012,000 2,858,000
Total liabilities 483,576,000 585,728,000
Commitments and Contingencies (Note 12)
Redeemable non-controlling interests 21,480,000 21,480,000
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023
Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2024 and December 31, 2023; 100,400 and 98,770 shares issued and outstanding at June 30, 2024 and December 31, 2023 1,004,000 988,000
Additional paid-in capital 1,660,862,000 1,643,641,000
Accumulated other comprehensive loss (3,809,000) (6,875,000)
Accumulated deficit (1,890,397,000) (1,841,920,000)
Total stockholders' deficit attributable to FibroGen (232,340,000) (204,166,000)
Nonredeemable non-controlling interests 20,487,000 20,487,000
Total deficit (211,853,000) (183,679,000)
Total liabilities, redeemable non-controlling interests and deficit $ 293,203,000 $ 423,529,000